How the body processes VX-407 after a single dose
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study gives a single dose of the study drug VX-407 to see how it is absorbed, broken down, and removed from the body. It helps researchers understand how the drug works in people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 55 years old (age requirement applies).
- Your body mass index (BMI) must be between 18.0 and 32.0.
- You must weigh more than 50 kilograms (about 110 pounds).
- You need to have regular bowel movements, meaning you have 1 to 3 stools per day.
- You must not have had a recent fever or other acute illness within 14 days before the study.
- You must not have been exposed to radiation from medical imaging or other sources in the past 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new drug, VX-407, affects the levels of a combined oral contraceptive in your body. Participants must be healthy adults aged 18 to 65 with a certain body weight and BMI.
This trial checks how a new drug interacts with two other medicines (amiodarone and febuxostat) in healthy volunteers. It helps doctors understand safe dosing before testing in patients.
This study is testing a new investigational medicine called PYC-003 for people with autosomal dominant polycystic kidney disease (ADPKD). It is one of the first studies in humans, so the main goal is to see if the medicine is safe and tolerable. The study is for people with a specific genetic cause (PKD1 mutation) and with certain kidney imaging types.
This study tests whether following a special diet for one week can help people with polycystic kidney disease. It aims to see if the diet is safe and if it can slow down the disease.
This study looks at how a new drug (JMKX003142) is absorbed and broken down in the body. It involves healthy men and will help determine safe dosing for future studies.
This study is for healthy volunteers to see how a new experimental drug (JMKX003142) interacts with other drugs in the body. It helps find the right dose for future patients.
Hear when a new Autosomal Dominant Polycystic Kidney Disease (ADPKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.